1
Chronic Respiratory Disease Research Center ( CRDRC ), National Research Institute of Tuberculosis and Lung Disease ( NRITLD ), Shahid Beheshti University of Medical Sciences, Tehran, Iran
2
Telemedicine Research Center of Masih Daneshvari Hospital, Chronic Kidney Disease Research Center, Shahid Beheshti university of Medical Sciences, Tehran, Iran
3
Pediatric Respiratory Disease Research Center, National Research Institute of Tuberculosis and Lung Disease ( NRITLD ), Shahid Beheshti University of Medical Sciences, Tehran, Iran
Yassari,F. , Mirenayat,M. S. , Fakharian,A. , Rashid-Farokhi,F. and Honarpisheh,P. (2023). Remdesivir in Patients with Advanced Renal Failure and COVID-19. TANAFFOS (Respiration), 22(3), 276-278.
MLA
Yassari,F. , , Mirenayat,M. S. , , Fakharian,A. , , Rashid-Farokhi,F. , and Honarpisheh,P. . "Remdesivir in Patients with Advanced Renal Failure and COVID-19", TANAFFOS (Respiration), 22, 3, 2023, 276-278.
HARVARD
Yassari F., Mirenayat M. S., Fakharian A., Rashid-Farokhi F., Honarpisheh P. (2023). 'Remdesivir in Patients with Advanced Renal Failure and COVID-19', TANAFFOS (Respiration), 22(3), pp. 276-278.
CHICAGO
F. Yassari, M. S. Mirenayat, A. Fakharian, F. Rashid-Farokhi and P. Honarpisheh, "Remdesivir in Patients with Advanced Renal Failure and COVID-19," TANAFFOS (Respiration), 22 3 (2023): 276-278,
VANCOUVER
Yassari F., Mirenayat M. S., Fakharian A., Rashid-Farokhi F., Honarpisheh P. Remdesivir in Patients with Advanced Renal Failure and COVID-19. TANAFFOS (Respiration), 2023; 22(3): 276-278.
